Janux Therapeutics JANX underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 3 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 1 | 0 | 0 |
Analysts have recently evaluated Janux Therapeutics and provided 12-month price targets. The average target is $74.0, accompanied by a high estimate of $100.00 and a low estimate of $42.00. A 3.65% drop is evident in the current average compared to the previous average price target of $76.80.
Interpreting Analyst Ratings: A Closer Look
The standing of Janux Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Dai | UBS | Announces | Buy | $69.00 | - |
| Josh Schimmer | Cantor Fitzgerald | Maintains | Overweight | $100.00 | $100.00 |
| Bradley Canino | Stifel | Announces | Buy | $70.00 | - |
| Swayampakula Ramakanth | HC Wainwright & Co. | Maintains | Buy | $63.00 | $63.00 |
| George Farmer | Scotiabank | Lowers | Sector Perform | $42.00 | $47.00 |
| Josh Schimmer | Cantor Fitzgerald | Maintains | Overweight | $100.00 | $100.00 |
| Robert Driscoll | Wedbush | Maintains | Outperform | $74.00 | $74.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Janux Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Janux Therapeutics compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Janux Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Janux Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Janux Therapeutics analyst ratings.
All You Need to Know About Janux Therapeutics
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
Key Indicators: Janux Therapeutics's Financial Health
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Janux Therapeutics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 741.72%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Janux Therapeutics's net margin excels beyond industry benchmarks, reaching -66.98%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.91%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Janux Therapeutics's ROA excels beyond industry benchmarks, reaching -0.86%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.04, Janux Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Significance of Analyst Ratings Explained
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
